ABSTRACT
Bile acids are synthesized from cholesterol through 17 different enzymes located in different intracellular compartments of hepatocytes. Defects have been identified in the genes encoding the enzymes involved in the bile acid synthesis pathways and nine different diseases have been identified so far. In this review, four different biosynthetic pathways of bile acids together with disorders of bile acid synthesis are described. In inborn errors of bile acid synthesis clinical findings can range from liver failure to cirrhosis in infancy or progressive neuropathy in adolescence/adulthood. Laboratory analysis of urine profiling of bile acids is important in early diagnosis and early treatment.
Key words: Cholesterol, Bile acids, Bile acid synthesis, Synthesis defect

INTRODUCTION
Bile acids are amphipathic molecules consisting of a 24-carbon steroid core and a carboxyl side chain [1,2]. Beside their role in the cholesterol catabolism, their amphipathic natures make them highly effective detergents in the digestion and absorption of dietary lipids and lipid-soluble vitamins in the small intestine [3]. Primary bile acids are synthesized by multistep enzymatic reactions involving 17 enzymes found in different intracellular compartments (endoplasmic reticulum, mitochondria, peroxisome, cytosol) of the hepatocytes [4]. Primary bile acids are then conjugated with glycine or taurine prior to secretion into bile [5]. Conjugation increases the water solubility of bile acids and reduces the passive diffusion during passage through the small intestine [6,7]. Conjugated bile acids are actively absorbed in the terminal ileum by specific receptors and enter to the
enterohepatic circulation where they return to the liver for further modification [3].
The synthesis of bile acid is tightly controlled to keep the bile acid concentrations at constant levels, since the accumulation of bile acids in liver and other tissues can be highly toxic [8].
In this review, four different biosynthetic pathways of bile acids together with the disorders of bile acid synthesis are described with the recent studies in the literature.

Chemical Structure and Properties of Bile Acids
Bile acids are amphipathic molecules. Hydroxyl groups are found on only one side of the molecule and give the molecule hydrophilic character. The other face does not contain hydroxyl groups and it is hydrophobic. Due to this amphipathic nature, increased bile acid concentrations decreases the surface tension. When a certain amount of bile acid is present in the water, the hydrophobic groups are clustered together and the hydrophilic groups are positioned towards the aqueous environment. Above a critical bile acid concentration, micelles are formed. This critical bile acid concentration is called critical micelle concentration (CMC). Surface tension remains constant above CMC, but increasing bile acid concentration increases the micelle concentration [9].
The hepatocytes synthesize two primary bile acids: Cholic acid (CA; 3α, 7α, 12α-trihydroxy-5β-cholanoic acid) and chenodeoxycholic acid (CDCA; 3α, 7α-dihydroxy-5β-cholanoic acid). They are often present as N-aminoacyl conjugates. All of the primary bile acids are α-hydroxylated. This polar hydrophilic group is on one side of the molecule that gives characteristic surface-active properties to bile acids. Deoxycholic acid (DCA; 3α, 12α-dihydroxy-5β-cholanoic acid) and lithocholic acid (LCA; 3α-monohydroxy-5β-cholanoic acid) are secondary bile acids, and formed by bacterial 7-dehydroxylation of CA and CDCA. Five percentage of total amount of bile acid is in the form of ursodeoxycholic acid (UDCA; 3α, 7β-dihydroxy-5β-cholanoic acid) which is formed in the liver and intestines [10,11].

Enterohepatic Circulation
The enterohepatic circulation of bile acids between the liver and intestine was first described by Borelli in 1681 [12,13]. Approximately 95% of the bile acids in the pool are recovered by the enterohepatic circulation. It also serves as a feedback mechanism in which cholesterol 7α-hydroxylase (CYP7A1) gene transcription and bile acid synthesis are inhibited to maintain bile acid homeostasis in humans [14].
The enterohepatic circulation of bile acids mainly consists of biosynthesis, secretion and reabsorption. After their synthesis from cholesterol by a series of enzymatic reactions in the liver, most of the bile acids stored in the gall bladder. By the stimulation of food intake, bile acids are released into the intestines through the bile duct and metabolized to secondary bile acids by intestinal bacterial flora [15]. Unconjugated bile acids are removed by passive diffusion in the jejunum and colon, while the conjugated bile acids are taken up into enterocytes by the apical sodium-dependent bile acid carrier (ASBT).
In total, 95% of bile acids are reabsorbed by enterocytes and the remaining is excreted through the feces. This amount (5%) is compensated by de novo bile acid synthesis in the hepatocytes [16].

Pathways of Bile Acid Synthesis
The primary bile acids are synthesized from cholesterol with a complex series of reactions involving 17 different enzymes found in endoplasmic reticulum, mitochondria, cytoplasm and peroxisomes [17]. Recent studies have identified four major biosynthetic pathways of bile acids, named the Classic / Neutral pathway, the Alternative / Acidic pathway, the Yamasaki pathway and the 25-hydroxylation pathway [18,19] (Figure 1).
Cholesterol is a C27-sterol and has a double bond at position C5 (cholest-5-en-3β-ol). Cholesterol is converted into primary bile acids CA (3α, 7α, 12α-trihydroxy-5β-cholanoic acid) and CDCA (3α, 7α-dihydroxy-5β-cholanoic acid). One hydroxyl group (at C7α position) and two hydroxyl groups (at C7α and C12α positions) are added for the synthesis of CDCA and CA, respectively. The double bond at the 5-position is reduced; the 3β-hydroxyl group is converted to a 3α-hydroxyl group. The aliphatic side chain is oxidized to a carboxyl group and the structure is three carbon atoms shortened resulting in C24-cholanoic acid formation [19].

1. Classical / Neutral Pathway:
The classical or neutral pathway is the most important biosynthetic pathway responsible for the production of 90% of the total amount of bile acids [20]. It is named as neutral pathway because the intermediate metabolites are neutral sterols. This pathway is only in the liver and synthesizes two primary bile
acids, CA (trihydroxy-bile acid with hydroxyl groups at C3, C7 and C12) and CDCA (dihydroxy-bile acid with hydroxyl groups at C3 and C7) [21,22]. CA and CDCA are synthesized at almost equal amounts in this pathway [23,24].

The classical pathway of bile acid synthesis begins with the rate-limiting enzyme cholesterol 7α-hydroxylase (CYP7A1). The reaction of CYP7A1 produces 7α-hydroxycholesterol which is converted to 7α-hydroxy-4-cholesten-3-one. 7α-hydroxy-4-cholesten-3-one is a common precursor of CA and CDCA which are synthesized in the subsequent reaction steps. It is also called C4 and currently used as a biomarker in determining the rate of bile acid synthesis. CA is formed from C4 by the action of sterol 12α-hydroxylase (CYP8B1), whereas CDCA is formed in the absence of CYP8B1. The ratio of 12α-hydroxylated bile acids (CA and DCA) to 12α-non-hydroxylated bile acids (CDCA and LCA) in the bile acid pool is determined by the CYP8B1. Subsequently, steroid side chain oxidation reactions take place by mitochondrial enzyme sterol 27-hydroxylase (CYP27A1), and followed by the removal of the propionyl group for the formation of C24 bile acids with peroxisomal β-oxidation [14].

2. Alternative / Acidic Pathway:
In the alternative biosynthetic pathway for bile acids, side chain oxidation of cholesterol occurs before steroid ring modification [25,26]. Thus, acidic intermediate metabolites are formed and it is named as acidic pathway [25,27]. It is initiated by mitochondrial enzyme CYP27A1 which is expressed in macrophages and many other tissues [28]. Both pathways can synthesize CA and CDCA, but the alternative / acidic pathway is believed to produce mainly CDCA [29]. CYP27A1 in the inner membrane of mitochondria catalyzes the first hydroxylation reaction to convert cholesterol to 27-hydroxycolesterol (3β-hydroxy-5-cholestenoic acid) [27,30]. The monohydroxy C-27 bile acid then undergoes hydroxylation at the C-7 position with oxysterol 7α-hydroxylase (CYP7B1) to form 3β, 7α-dihydroxy-5-cholestenic acid [27,31]. Subsequently, 3β-hydroxy-5-C27-sterol oxidoreductase (HSD3B7) initiates sterol nuclear modifications and the same enzymes that are used in the classical pathway complement ring structure modifications [32].

3. Yamasaki Pathway:
C24 bile acids and 3β-hydroxy-5-cholestenic acid in the Yamasaki pathway are formed in a similar way as in the alternative / acidic way. After this step, the hydroxylation reaction carried out by the enzyme 7α-hydroxylase in humans produces 3β, 7α-dihydroxy-5-cholestenic acid. It is the CDCA precursor, and at the last step of the reactions CDCA occurs [33]. CDCA is thought to be the main product of the Yamasaki pathway in humans. The exact contribution of the Yamasaki pathway to the bile acid pool in humans has not been fully established. However, the presence of monohydroxy bile acids in fetal bile and the relatively high levels of these bile acids in meconium and amniotic fluid suggest that this pathway is at least important during development [34].

4. 25-hydroxylation Pathway:
After completion of the ring structure modifications, C24-carboxylic acid is obtained by 25-hydroxylation instead of sterol 27-hydroxylation reactions and peroxisomal β-oxidation. The formation of 3α, 7α, 12α-trihydroxy-25-cholestane-5β-24-one is catalyzed by the microsomal sterol 25-hydroxylase (CH25H). Subsequent dehydroxylation reactions producing 24-oxo-petroleum reduced to CA and acetone [33].

Bile Acid Conjugation
Primary bile acids synthesized by the enzymatic reactions in the liver, are conjugated with glycine and taurine with amidation reactions at carboxyl groups. The conjugation reaction is mediated by two enzymes: Bile acid coenzyme A synthase (BACS) and bile acid CoA-amino acid N-acyltransferase (BAAT) [12]. (Figure 1)
Figure 1. Biosynthetic pathways of bile acids.
Conjugation with amino acids significantly increases the polarity of the molecule [21]. Unconjugated bile acids have about 5 pKa. Conjugation reduces pKa of bile acids, increases water solubility, and reduces their ability to cross lipid membranes [10].

Defects of Bile Acid Synthesis

Inborn errors of bile acid synthesis (IEBAS) are rare genetic disorders of liver metabolism that cause chronic liver disease and fat-soluble vitamin deficiencies in childhood [35,36]. These defects are characterized by the inability to produce normal bile acids. There is accumulation of unusual bile acid and bile acid intermediates due to enzyme defects in the bile acid biosynthetic pathways from cholesterol [37,38]. Although 17 enzymes are present in the bile acid biosynthetic pathway, only 9 types of IEBAS have been identified to date [39] (Table 1).

Table 1. Inborn Errors of Bile Acid Synthesis

| Disorder | OMIM | Gene | Abbreviation | Alternative name | Affected Protein |
|----------|------|------|--------------|------------------|-----------------|
| 3β-Hydroxy-Δ5-C27-sterol dehydrogenase/isomerase deficiency | 607764 | HSD3B7 | C27-3β-HSD | 3β-Dehydrogenase deficiency | 3β-Hydroxy-Δ5-C27-sterol dehydrogenase/isomerase deficiency |
| Δ4-3-Oxosteroid-5β-reductase deficiency | 604741 | AKR1D1 | SRD5B1 | 5β-Reductase deficiency | Δ4-3-Oxosteroid-5β-reductase |
| Oxysterol 7α-hydroxylase deficiency | 603711 | CYP7B1 | CYP7B1 | Spastic Paraplegia 5A | Oxysterol 7α-hydroxylase |
| Cholesterol 7α-hydroxylase deficiency | 118455 | CYP7A1 | CYP7A1 | | Cholesterol 7α-hydroxylase |
| Sterol 27-hydroxylase deficiency | 213700 | CYP27A1 | CTX | Cerebrotendinous Xanthomatosis | Sterol 27-hydroxylase |
| α-Methylacyl-CoA racemase deficiency | 604489 | AMACR | AMACR | AMACR deficiency | α-Methylacyl-CoA racemase |
| Bile acid-CoA: amino acid N-acyltransferase deficiency | 602938 | BAAT | BAAT | Bile acid amidation defect | Bile acid-CoA: amino acid N-acyltransferase |
| Bile acid-CoA ligase deficiency | 603314 | SLC27A5 | BA CoA LD | | Bile acid-CoA ligase |
| ATP8B1 deficiency | 211600 | ATP8B1 | PFIC1 | Progressive familial intrahepatic cholestasis type 1 | ATP8B1 (type 4 P-type ATPase) |

Long-term jaundice in the neonatal period is one of the main findings of IEBAS. In cases of obstructive jaundice with normal levels of total cholesterol and gamma-glutamyl transeptidase (GGT); hepatic dysfunction or cirrhosis with an unknown cause; family history of hepatic dysfunction; no improvement with the treatments after a diagnosis of neonatal hepatitis; clinical symptoms similar to tyrosinemia; no itching despite cholestasis; recurrent diarrhea or steatorrhea; symptoms of fat-soluble vitamin deficiency (intracranial hemorrhage, rickets, hypocalcemic seizures, etc.), IEBAS should be considered. To date, 9 types of IEBAS have been discovered. Urine bile acid profiling is an important tool in the diagnosis of IEBAS (Table 2).
1. 3β-Hydroxy-Δ5-C27-steroid dehydrogenase / isomerase deficiency: 3β-hydroxy-Δ5-C27-steroid dehydrogenase (HSD3B7) is the first discovered disorder of bile acid synthesis [40]. It is also the most common defect in bile acid synthesis [41,42]. The estimated prevalence in Europe is 0.99 per 10 million [43] and only 53 cases have been reported to date [44]. Although clinical symptoms (cholestasis, bleeding tendency, rickets, developmental disorder, etc.) vary in patients, GGT and total bile acid (TBA) concentrations are generally within normal limits [42]. High levels of sulfated 3β, 7α-dihydroxy-5-cholestenoic acid and 3β, 7α-trihydroxy-5-cholestenoic acid are determined in the urine or blood [45]. Serum liver enzymes may be normal in the early stages of the disorder, but then show gradual increases [46].

2. Δ4-3-Oxosteroid-5β-reductase deficiency: This deficiency in bile acid synthesis is due to a defect in the aldo-ketoreductase family 1 member D1 (AKR1D1) gene, which encodes the key enzyme Δ4-oxosteroid 5β-reductase [47]. This enzyme catalyzes the reduction of Δ4-3-ketosteroid AB to form the cis ring structure AB [48]. The deficiency of this cytosolic enzyme results in misreduction of the double bond between the C-4 and C-5 of the sterol A-ring, which is the basic step in major bile acid synthesis. Thus, there is a misconversion of the 3-oxo intermediates to the corresponding 3α-hydroxyl products. This deficiency results in significantly reduced primary bile acid synthesis and deposition of 3-oxo-Δ4 and allo (5α-H) - bile acids [32,49]. Accumulated unsaturated C27-3-oxo-Δ4 steroids are converted to the corresponding C24-bile acids and can be detected in both blood and urine [19]. The main findings in 5β-reductase deficiency are normal or slightly elevated TBA and GGT in blood; high levels of conjugated bilirubin and alanine aminotransferase (ALT), and steatorrhea.

3. Oxysterol 7α-hydroxylase deficiency: Oxysterol 7α-hydroxylase deficiency is caused by mutations in the CYP7B1 gene encoded by 6 exons on chromosome 8q21.3 [50]. Oxysterol 7α-hydroxylase converts 3β-hydroxy-5-cholestenoic acid to 3β, 7α-dihydroxy-5-cholestenoic acid, particularly an important step in the acidic pathway in the first year of life [51]. This deficiency has the lowest prevalence in known IEBAS [52]. Only 4 cases have been reported to date and clinical signs or prognosis have not been clearly clarified [39].

4. Cholesterol 7α-hydroxylase deficiency: Cholesterol 7α-hydroxylase is found in the endoplasmic reticulum and expressed only in the liver. It is the rate-limiting step of bile acid synthesis [21]. It is located in the classical pathway, the main bile acid biosynthetic pathway in adults. Since the alternative pathway can still produce bile acids via oxysterol 7α-hydroxylase, CYP7A1 defect does not cause deficiency in bile acids [53].
5. Sterol 27-hydroxylase deficiency: Cerebrotendinous Xanthomatosis (CTX) is a lipid storage disease that affects many organs and systems. It is characterized by abnormal accumulation of cholesterol and cholestanol resulting in neurological dysfunction (dementia, spinal cord paresis and cerebellar ataxia), peritendinous xanthomas, early atherosclerosis and cataracts [54]. It is caused by mutations in the CYP27A1 gene encoding sterol 27-hydroxylase. The defect blocks the initial modification of the cholesterol side chain, which leads to a reduction in the synthesis of primary bile acids together with the production and excretion of bile alcohols [55]. As a result of CYP27A1 deficiency, 5α-cholestanol (a 5α-dihydro cholesterol derivative) is accumulated in the tissues. Intense accumulation of 5α-cholestanol in the brain results in severe neurological dysfunction [56]. The increase in 5α-cholestan-3β-ol in the nervous system and high levels of this sterol in blood are unique features of CTX patients [57,58].

6. α-Methylacyl-CoA racemase deficiency: 2-methylacyl-CoA racemase (AMACR) is an enzyme of the β-oxidation system in both peroxisome and mitochondria. AMACR deficiency is caused by mutations in the AMACR [59]. A deficiency in this enzyme disturbs bile acid side chain oxidation, which leads to high concentrations of (25R)−taurohydrocholic acid (THCA) in urine, bile and blood [60]. Therefore, AMACR deficiency causes accumulation of (25R)−pyristanic acid, (25R)−THCA and (25R)−dihydrocholic acid (DHCA) in blood, cells and tissues [59]. This enzyme deficiency has profound effects on both bile acid and fatty acid pathways [60].

7. Bile acid-CoA: amino acid N-acyltransferase deficiency: Conjugation of CA and CDCA with an amide bond to C-24 of an amino acid (taurine or glycine) is the final step in primary bile acid synthesis [61]. BAAT deficiency is caused by mutations in the BAAT gene encoding the liver-specific bile acid-CoA: amino acid N-acyltransferase (a peroxisomal enzyme), which converts CoA esters of bile acids into taurine or glycine conjugates [38].

8. Bile acid-CoA ligase deficiency: The final step in bile acid synthesis involves conjugation with amino acid glycine and taurine [62]. The two enzymes catalyze reactions that lead to amidation of bile acids. First, a CoA thioester is formed by the rate-limiting enzyme bile acid-CoA ligase, followed by the combination of glycine or taurine in a reaction catalyzed by a cytosolic BAAT [52]. BACS is the first enzyme required for amidation of primary bile acids and converts C24-bile acids into their corresponding bile acyl-CoAs [63]. CoA is then replaced by BAAT with taurine or glycine. BACS is a liver-specific enzyme found in the endoplasmic reticulum and is required for the conjugation of bile acids deconjugated by enterohepatic circulating intestinal bacteria [64]. Due to a homozygous mutation in SLC27A5, only two siblings were identified with BACS deficiency [65].

9. ATP8B1 deficiency: Progressive familial intrahepatic cholestasis (PFIC) is a bile acid deficiency that accounts for approximately 10% to 15% of cholestatic liver disease in children [66]. The estimated prevalence of PFICs is 1 / 50,000 to 1 / 100,000 [66,67]. Three subtypes of PFIC (PFIC1, PFIC2, PFIC3) have been identified [68]. PFIC is caused by mutations in the ATP8B1 gene on the chromosome 18q21-q22 encoding type 1 FIC1 protein [69]. The main clinical features of PFIC are cholestasis, jaundice and pruritus. These clinical features typically occur during infancy or early childhood [68].

CONCLUSION

In IEBAS clinical findings can range from liver failure to cirrhosis in infancy or progressive neuropathy in adolescence or adulthood. Early diagnosis is important for early treatment and crucial to prevent fatal outcomes in which urine bile acid profiling is an important tool [38,39].

CONFLICT of INTEREST

There is no conflict of interest.
REFERENCES

[1] Di Ciaula A, Garruti G, Lunardi Baccetto R, et al. Bile Acid Physiology. Ann Hepatol 2017; 16: 4-14.
[2] Thomas C, Pelliccieri R, Pruzenski M, et al. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 2008; 7(8): 678-93.
[3] Ikegami T, Honda AN. Reciprocal interactions between bile acids and gut microbiota in human liver diseases. Hepatol Res 2018; 48(1): 15-27.
[4] Martinot E, Sèdes L, Baptissart M, et al. Bile acids and their receptors. Mol Aspects Med 2017; 56: 2-9.
[5] Prawitt J, Caron S, Staels B. Bile acid metabolism and the pathogenesis of type 2 diabetes. Curr Diab Rep 2011; 11(3): 160-6.
[6] Degirolamo C, Rainaldi S, Bovenga F, et al. Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice. Cell Rep 2014; 10; 71(1): 12-8.
[7] Pavlidis P, Powell N, Vincent RP, et al. Systematic review: bile acids and intestinal inflammation-luminal aggressors or regulators of mucosal defence? Aliment Pharmacol Ther 2015; 42(7): 802-17.
[8] Chiang JYL, Ferrell JM. Bile Acid Metabolism in Liver Pathobiology. Gene Expr 2018; 18; 18(2): 71-87.
[9] Eggert T, Bakonyi D, Hummel W. Enzymatic routes for the synthesis of ursodeoxycholic acid. J Biotechnol 2014; 10; 191:11-21.
[10] Hofmann AF, Mye J, Sjövall J. Bile acid solubility and precipitation in vitro and in vivo: the role of conjugation, pH, and Ca2+ ions. J Lipid Res 1992; 33 (5): 617-26.
[11] Walker IA, Nelson-Piercy C, Williamson C. Role of bile acid measurement in pregnancy. Ann Clin Biochem 2002; 39 (Pt 2):105-13.
[12] Hofmann AF. The enterohepatic circulation of bile acids in mammals: form and functions. Front Biosci 2009; 14: 2584-2598.
[13] Borelli G. De Motu animalium, Pars altera. Angeli Bernabo, Rome. English translation by P. Gosse, The Hague, Netherlands. 1743. Reprinted in 1899 by Springer, Berlin. 1681; 354–364.
[14] Chiang JY. Recent advances in understanding bile acid homeostasis. F1000Res 2017; 20; 6: 209.
[15] Gonzalez FJ. Nuclear receptor control of enterohpatic circulation. Compr Physiol 2012; 2(4): 2811-28.
[16] Mertens KL, Kalsbeek A, Soeters MR, et al. Bile Acid Signaling Pathways from the Enterohpatic Circulation to the Central Nervous System. Front Neurosci 2017; 7; 11: 617.
[17] Dawson PA and Karpfen SJ. Intestinal transport and metabolism of bile acids. J Lipid Res 2015; 56(6): 1085–1099.
[18] Šarenac TM, Mikov M. Bile Acid Synthesis: From Nature to Chemical Modification and Synthesis and Their Applications as Drugs and Nutrients. Fronton Pharmacol 2018; 25; 9: 939.
[19] Vaz FM, Ferdinandasius S. Bile acid analysis in human disorders of bile acid biosynthesis. Mol Aspects Med 2017; 56; 10: 24.
[20] Norlin M, Wikvall K. Enzymes in the conversion of cholesterol into bile acids. Curr Mol Med 2007; 7(2): 199-218.
[21] Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 2003; 72:137-74.
[22] Chiang JY. Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms. J Hepatol 2004; 40(3): 539-51.
[23] Chiang JY. Bile acids: regulation of synthesis. J Lipid Res 2009; 50(10): 1955-66.
[24] Björkhem I, Leoni V, Meaney S. Genetic connections between neurological disorders and cholesterol metabolism. J Lipid Res 2010; 51(9): 2489-503.
[25] Axelson M, Sjövall J. Potential bile acid precursors in plasma—possible indicators of biosynthetic pathways to cholic and chenodeoxycholic acids in man. J Steroid Biochem 1990; 28; 36(6): 631-40.
[26] Boyer JL. Bile formation and secretion. Compr Physiol 2013; 3(3): 1035-78.
[27] Li T, Chiang JY. Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev 2014; 66(4): 948-83.
[28] Hylemon P, Zhou H, Pandak WM, et al. Bile acids as regulatory molecules. J Lipid Res 2009; 50(8): 1509-20.
[29] Ellis EC. Suppression of bile acid synthesis by thyroid hormone in primary human hepatocytes. World J Gastroenterol 2006; 7; 12(29): 4640-5.
[30] De Fabiani E, Mitro N, Anzulovich AC, et al. The negative effects of bile acids and tumor necrosis factor-alpha on the transcription of cholesterol 7alpha-hydroxylase gene (CYP7A1) converge to hepatic nuclear factor-4: a novel mechanism of feedback regulation of bile acid synthesis mediated by nuclear receptors. J Biol Chem 2001; 17; 276(33): 30708-16.
[31] Björkhem I, Diczfalusy U. Oxy sterols: friends, foes, or just fellow passengers? Arterioscler Thromb Vasc Biol 2002; 1; 22(5): 734-42.
[32] Setchell KD, Dumawala R, Kolombo C, et al. Hepatic bile acid metabolism during early development revealed from the analysis of human fetal gallbladder bile. J Biol Chem 1988; 15; 263(32): 16637-44.
[33] Kevresan S, Kuhajda K, Kandrac J, et al. Biosynthesis of bile acids in mammalian liver. Eur J Drug Metab Pharmacokinet 2006; 31(3): 145-56.
[34] Nakagawa M, Setchell KD. Bile acid metabolism in early life: studies of amniotic fluid. J Lipid Res 1990; 31(6): 1089-98.
[35] Haas D, Gan-Schreier H, Langhans CD, et al. Differential diagnosis in patients with suspected bile acid synthesis defects. World J Gastroenterol 2011; 14;18(10):1067-76.
[36] Monte MJ, Marin JJ, Antelo A, et al. Bile acids: chemistry, physiology, and pathophysiology. World J Gastroenterol 2009; 21;15(7):804-16.
[37] Donazzolo E, Gucziardi A, Mazzier D, et al. Improved synthesis of glycine, taurine and sulfate conjugated bile acids as reference compounds and internal standards for ESI-MS/MS urinary profiling of inborn errors of bile acid synthesis. Chem Phys Lipids 2017; 204:43-56.
[38] Clayton PT. Disorders of bile acid synthesis. J Inherit Metab Dis 2011; 34(3):593-604.
[39] Hong J, Oh SH, Yoo HW, et al. Complete Recovery of Oxy sterol 7a-Hydroxylase Deficiency by Living Donor Transplantation in a 4-Month-Old Infant: the First Korean Case
Bile Acid Synthesis and Defects

Report and Literature Review. J Korean Med Sci 2018; 22;33(S1): e324.

[40] Clayton PT, Leonard JV, Lawson AM, et al. Familial giant cell hepatitis associated with synthesis of 3 beta, 7 alpha-dihydroxy-and 3 beta,7 alpha, 12 alpha-trihydroxy-5-choleenoic acids. J Clin Invest. 1987; 79: 1031–1038.

[41] Cheng JB, Jacquemin E, Gerhardt M, et al. Molecular genetics of 3beta-hydroxy-Delta5-C27-steroid oxidoreductase deficiency in 16 patients with loss of bile acid synthesis and liver disease. J Clin Endocrinol Metab. 2003;88(4):1833–1841.

[42] Subramaniam P, Clayton PT, Portmann BC, et al. Variable clinical spectrum of the most common inborn error of bile acid metabolism-3beta-hydroxy-Delta 5-C27-steroid dehydrogenase deficiency. J Pediatr Gastroenterol Nutr. 2010; 50: 61–66.

[43] Jahnel J, Zöhrer E, Fischler B, et al. Attempt to determine the prevalence of two inborn errors of primary bile acid synthesis: results of a European survey. J Pediatr Gastroenterol Nutr. 2017; 64: 864–868.

[44] Matarazzo L, Martelossi S, Chiaffoni GP, et al. A Familial non-itching cholestasis. Dig Liver Dis 2014;46: 105-6.

[45] Setchell KDR, O’Connell NC. Disorders of bile acid synthesis and metabolism: a metabolic basis for liver disease in children. In: Suchy FJ, Sokol RJ, Balisteri WF, editors. Liver disease in children. Third Edition ed Cambridge University Press; 2007; 736–766.

[46] Bove KE, Daugherty CC, Tyson W, et al. Bile acid synthetic defects and liver disease. Pediatr Dev Pathol 2000; 3:1-16.

[47] Drury JE, Mindnich R, Penning TM. Characterization of disease-related 5beta-reductase (AKR1D1) mutations reveals their potential to cause bile acid deficiency. J Biol Chem. 2010; 285: 24529–24537.

[48] Kondo KH, Kai MH, Setoguchi Y, et al. Cloning and expression of cDNA of human delta 4-3-oxosteroid 5 beta-reductase and substrate specificity of the expressed enzyme. Eur J Biochem. 2010; 285: 357–363.

[49] Seki Y, Mizuochi T, Kimura A, et al. Two neonatal cholestasis patients with mutations in the SRD5B1 (AKR1D1) gene: diagnosis and bile acid profiles during chenodeoxycholic acid treatment. J Inherit Metab Dis. 2013;36(3):565-573.

[50] Ueki I, Kimura A, Nishiyori A, et al. Neonatal cholestatic liver disease in an Asian patient with a homozygous mutation in the oxysterol 7alpha-hydroxylase gene. J Pediatr Gastroenterol Nutr. 2008; 46: 465-469.

[51] Craigen WJ. Chapter 160. Disorders of bile acid synthesis. In: Kline MW, editor. Rudolph’s Pediatrics. 23rd ed. New York, NY; McGraw-Hill Education; 2018.

[52] Heubi JE, Setchell KDR, Bove KE. Inborn Errors of Bile Acid Metabolism. Semin Liver Dis. 2007; 27: 282–294.

[53] Pullinger CR, Eng C, Salen G, et al. Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J Clin Invest. 2002; Jul; 110(1):109-17.

[54] Mignarri A, Gallus GN, Dotti MT, et al. A suspicion index for early diagnosis and treatment of cerebrotendinous xanthomatosis. J Inherit Metab Dis. 2014; 37:421–429.

[55] Shimazu K, Kuwabara M, Yoshii M, et al. Bile alcohol profiles in bile, urine, and feces of a patient with cerebrotendinous xanthomatosis. J. Biochem, 1986; 99(2), 477-483.

[56] Menkes JH, Schimshock JR, Swanson PD. Cerebrotendinous xanthomatosis. The storage of cholesterol within the nervous system. Arch Neurol. 1968; Jul;19(1):47-53.

[57] Salen G, Shefer S, Tint G S, et al. Biosynthesis of bile acids in cerebrotendinous xanthomatosis: relationship of bile acid pool sizes and synthesis rates to hydroxylations at C-12, C-25, and C-26. J Clin Invest. 1985; 76:744-751.

[58] Koopman BJ, van der Molen JC, Wolthers BG, et al. Capillary gas chromatographic determination of cholesterol/cholesterol ratio in biological fluids: its potential usefulness for the follow-up of some liver diseases and its lack of specificity in diagnosing CTX (cerebrotendinous xanthomatosis). Clin Chim Acta. 1984; 137 305-315.

[59] Ferdinandusse S, Denis S, Ulst L, et al. Subcellular localization and physiological role of alpha-methylacyl-CoA racemase. J Lipid Res. 2000; 41: 1890–1896.

[60] Ferdinandusse S, Overmars H, Denis S, et al. Plasma analysis of di- and trihydroxycholestanolic acid diastereoisomers in peroxisomal alpha-methylacyl-CoA racemase deficiency. J Lipid Res. 2001; 42: 137–141.

[61] Suchy FJ, Sokol RJ, Balisteri WF. Liver Disease in Children. 3rd ed. Cambridge University Press, Cambridge. 2007; 736-766.

[62] Sjovall J. Dietary glycine and taurine conjugation in man. Proc Soc Exp Biol Med. 1959; 100 676-678.

[63] Hubbard B, Doehe H, Punreedy S, et al. Mice deleted for fatty acid transport protein 5 have defective bile acid conjugation and are protected from obesity. Gastroenterology, 130, 2006; 1259-1269.

[64] Steinberg SJ, Mihalik SJ, Kim DG, et al. The human liver-specific homolog of very long-chain acyl-CoA synthetase is cholate: CoA ligase. J. Biol. Chem, 275, 2000; 15605-15608.

[65] Chong CP, Mills PB, McClean P, et al. Bile acid-CoA ligase deficiency—a new inborn error of bile acid metabolism. J Inherit Metab Dis. 2012 May;35(3):521-530.

[66] Davit-Spraul A, Frulloni L, Cerati E, et al. Progressive familial intrahepatic cholestasis. Acta Biomed. 2002;73:53–56.

[67] Cavestro GM, Frulloni L, Cerati E, et al. Progressive familial intrahepatic cholestasis. Acta Biomed. 2002;73:53–56.

[68] Srivastava A, Giansella E, Balistreri WF, et al. The clinical spectrum of the most common inborn error of bile acid synthesis: results of a European survey. J Pediatr Gastroenterol Nutr. 2017; 64: 864–868.

[69] Pullinger CR, Eng C, Salen G, et al. Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J Clin Invest. 2002; Jul; 110(1):109-17.

© 2019 Acta Medica. All rights reserved.